In addition, blocking the downstream pathways activated by LYPD3 and its ligand AGR2 facilitated the progress of endocrine therapy-resistant breast cancer and pancreatic carcinoma 76,77. This evidence concerns the gene LYPD3 and exocrine pancreatic carcinoma.